Nuclear Mechanisms of Insulin Resistance

Trends in Cell Biology

Volumn 26, Issue 5, 2016, Pages 341-351

  Kang, Sona ^a,b   Tsai, Linus T Y ^a   Rosen, Evan D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID RECEPTOR; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FKHR; CELL RECEPTOR;

CYTOSOL; EPIGENETICS; GENETIC TRANSCRIPTION; HORMONE ACTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ADIPOSE TISSUE; ANIMAL; BIOLOGICAL MODEL; CELL NUCLEUS; HUMAN; METABOLISM;

ADIPOSE TISSUE; ANIMALS; CELL NUCLEUS; HUMANS; INSULIN RESISTANCE; MODELS, BIOLOGICAL; PPAR GAMMA; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84955619589     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2016.01.002     Document Type: Review

References (99)

1. Menke A., et al. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA 2015, 314:1021-1029.
2. Boucher J., et al. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb. Perspect. Biol. 2014, 6:a009191.
3. Biddinger S.B., Kahn C.R. From mice to men: insights into the insulin resistance syndromes. Annu. Rev. Physiol. 2006, 68:123-158.
4. Huang-Doran I., Savage D.B. Congenital syndromes of severe insulin resistance. Pediatr. Endocrinol. Rev. 2011, 8:190-199.
5. Hotamisligil G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010, 140:900-917.
6. Houstis N., et al. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006, 440:944-948.
7. James A.M., et al. Mitochondrial oxidative stress and the metabolic syndrome. Trends Endocrinol. Metab. 2012, 23:429-434.
8. Olefsky J.M., Glass C.K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 2010, 72:219-246.
9. Kang S., et al. Identification of nuclear hormone receptor pathways causing insulin resistance by transcriptional and epigenomic analysis. Nat. Cell Biol. 2015, 17:44-56.
10. Cleasby M.E., et al. Functional studies of Akt isoform specificity in skeletal muscle in vivo; maintained insulin sensitivity despite reduced insulin receptor substrate-1 expression. Mol. Endocrinol. 2007, 21:215-228.
11. Hoehn K.L., et al. IRS1-independent defects define major nodes of insulin resistance. Cell Metab. 2008, 7:421-433.
12. Kim Y.B., et al. Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J. Clin. Invest. 1999, 104:733-741.
13. Nadler S.T., et al. Normal Akt/PKB with reduced PI3K activation in insulin-resistant mice. Am. J. Physiol. Endocrinol. Metab. 2001, 281:E1249-E1254.
14. Ahmadian M., et al. PPARgamma signaling and metabolism: the good, the bad and the future. Nat. Med. 2013, 19:557-566.
15. Soccio R.E., et al. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 2014, 20:573-591.
16. Masuccio F., et al. Weight gain and insulin resistance in children treated with valproate: the influence of time. J. Child Neurol. 2010, 25:941-947.
17. Inagaki T., et al. Obesity and metabolic syndrome in histone demethylase JHDM2a-deficient mice. Genes Cells 2009, 14:991-1001.
18. Ohno H., et al. EHMT1 controls brown adipose cell fate and thermogenesis through the PRDM16 complex. Nature 2013, 504:163-167.
19. Tateishi K., et al. Role of Jhdm2a in regulating metabolic gene expression and obesity resistance. Nature 2009, 458:757-761.
20. Rando O.J., Simmons R.A. I'm eating for two: parental dietary effects on offspring metabolism. Cell 2015, 161:93-105.
21. Kyle U.G., Pichard C. The Dutch famine of 1944-1945: a pathophysiological model of long-term consequences of wasting disease. Curr. Opin. Clin. Nutr. Metab. Care 2006, 9:388-394.
22. Raychaudhuri N., et al. Histone code modifications repress glucose transporter 4 expression in the intrauterine growth-restricted offspring. J. Biol. Chem. 2008, 283:13611-13626.
23. Odegaard J.I., Chawla A. The immune system as a sensor of the metabolic state. Immunity 2013, 38:644-654.
24. Tomas E., et al. Metabolic and hormonal interactions between muscle and adipose tissue. Proc. Nutr. Soc. 2004, 63:381-385.
25. Parlevliet E.T., et al. The brain modulates insulin sensitivity in multiple tissues. Front. Horm. Res. 2014, 42:50-58.
26. Mathis D. Immunological goings-on in visceral adipose tissue. Cell Metab. 2013, 17:851-859.
27. Eguchi J., et al. Interferon regulatory factor 4 regulates obesity-induced inflammation through regulation of adipose tissue macrophage polarization. Diabetes 2013, 62:3394-3403.
28. Chao L., et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest. 2000, 106:1221-1228.
29. He W., et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:15712-15717.
30. Sugii S., et al. PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:22504-22509.
31. Hevener A.L., et al. Muscle-specific PPARγ deletion causes insulin resistance. Nat. Med. 2003, 9:1491-1497.
32. Norris A.W., et al. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Invest. 2003, 112:608-618.
33. Rosen E.D., et al. Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol. Cell. Biol. 2003, 23:7222-7229.
34. Bouhlel M.A., et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007, 6:137-143.
35. Odegaard J.I., et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
36. Hevener A.L., et al. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 2007, 117:1658-1669.
37. Pascual G., et al. Macrophage peroxisome proliferator activated receptor gamma as a therapeutic target to combat type 2 diabetes. Expert Opin. Ther. Targets 2007, 11:1503-1520.
38. Cipolletta D., et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012, 486:549-553.
39. Lu M., et al. Brain PPAR-gamma promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat. Med. 2011, 17:618-622.
40. Ryan K.K., et al. A role for central nervous system PPAR-gamma in the regulation of energy balance. Nat. Med. 2011, 17:623-626.
41. Ye J.M., et al. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia 2004, 47:1306-1313.
42. Iwata M., et al. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-gamma. Diabetes 2001, 50:1083-1092.
43. Jiang G., et al. Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists. Diabetes 2002, 51:2412-2419.
44. Ohno H., et al. PPARgamma agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell Metab. 2012, 15:395-404.
45. Qiang L., et al. Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ. Cell 2012, 150:620-632.
46. Vernochet C., et al. C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists. Mol. Cell. Biol. 2009, 29:4714-4728.
47. Riera-Guardia N., Rothenbacher D. The effect of thiazolidinediones on adiponectin serum level: a meta-analysis. Diabetes Obes. Metab. 2008, 10:367-375.
48. Lefterova M.I., et al. PPARgamma and the global map of adipogenesis and beyond. Trends Endocrinol. Metab. 2014, 25:293-302.
49. Rangwala S.M., et al. Genetic modulation of PPARγ phosphorylation regulates insulin sensitivity. Dev. Cell 2003, 5:657-663.
50. Choi J.H., et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010, 466:451-456.
51. Choi J.H., et al. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 2011, 477:477-481.
52. Banks A.S., et al. An ERK/Cdk5 axis controls the diabetogenic actions of PPARgamma. Nature 2015, 517:391-395.
53. Dutchak P.A., et al. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell 2012, 148:556-567.
54. Oakley R.H., Cidlowski J.A. Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids. J. Biol. Chem. 2011, 286:3177-3184.
55. Patel R., et al. Minireview: new molecular mediators of glucocorticoid receptor activity in metabolic tissues. Mol. Endocrinol. 2014, 28:999-1011.
56. Plotz C.M., et al. Natural course of Cushing's syndrome as compared with the course of rheumatoid arthritis treated by hormones. Ann. Rheum. Dis. 1952, 11:308-309.
57. Rizza R.A., et al. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J. Clin. Endocrinol. Metab. 1982, 54:131-138.
58. Roohk D.J., et al. Dexamethasone-mediated changes in adipose triacylglycerol metabolism are exaggerated, not diminished, in the absence of a functional GR dimerization domain. Endocrinology 2013, 154:1528-1539.
59. Wang J.C., et al. Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:15603-15608.
60. Lowenberg M., et al. Kinome analysis reveals nongenomic glucocorticoid receptor-dependent inhibition of insulin signaling. Endocrinology 2006, 147:3555-3562.
61. Opherk C., et al. Inactivation of the glucocorticoid receptor in hepatocytes leads to fasting hypoglycemia and ameliorates hyperglycemia in streptozotocin-induced diabetes mellitus. Mol. Endocrinol. 2004, 18:1346-1353.
62. Yi C.X., et al. Glucocorticoid signaling in the arcuate nucleus modulates hepatic insulin sensitivity. Diabetes 2012, 61:339-345.
63. Castonguay T.W. Glucocorticoids as modulators in the control of feeding. Brain Res. Bull. 1991, 27:423-428.
64. Kuo T., et al. Genome-wide analysis of glucocorticoid receptor-binding sites in myotubes identifies gene networks modulating insulin signaling. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:11160-11165.
65. Bodine S.C., et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 2001, 3:1014-1019.
66. Kitamura T. The role of FOXO1 in beta-cell failure and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2013, 9:615-623.
67. Morris A.P., et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat. Genet. 2012, 44:981-990.
68. Haeusler R.A., et al. FoxOs function synergistically to promote glucose production. J. Biol. Chem. 2010, 285:35245-35248.
69. Calabuig-Navarro V., et al. Forkhead Box O6 (FoxO6) depletion attenuates hepatic gluconeogenesis and protects against fat-induced glucose disorder in mice. J. Biol. Chem. 2015, 290:15581-15594.
70. Nakae J., et al. Forkhead transcription factor FoxO1 in adipose tissue regulates energy storage and expenditure. Diabetes 2008, 57:563-576.
71. Ren H., et al. FoxO1 target Gpr17 activates AgRP neurons to regulate food intake. Cell 2012, 149:1314-1326.
72. Calnan D.R., Brunet A. The FoxO code. Oncogene 2008, 27:2276-2288.
73. Kawamori D., et al. The forkhead transcription factor Foxo1 bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation. J. Biol. Chem. 2006, 281:1091-1098.
74. Greer E.L., et al. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J. Biol. Chem. 2007, 282:30107-30119.
75. Almeida M., et al. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J. Biol. Chem. 2007, 282:27298-27305.
76. Essers M.A., et al. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 2005, 308:1181-1184.
77. Ip W., et al. Liver-specific expression of dominant-negative transcription factor 7-like 2 causes progressive impairment in glucose homeostasis. Diabetes 2015, 64:1923-1932.
78. Daitoku H., et al. Regulation of FoxO transcription factors by acetylation and protein-protein interactions. Biochim. Biophys. Acta 2011, 1813:1954-1960.
79. Matsuzaki H., et al. Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:11278-11283.
80. Frescas D., et al. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J. Biol. Chem. 2005, 280:20589-20595.
81. Housley M.P., et al. O-GlcNAc regulates FoxO activation in response to glucose. J. Biol. Chem. 2008, 283:16283-16292.
82. Herzig S., et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 2001, 413:179-183.
83. Yoon J.C., et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001, 413:131-138.
84. Puigserver P., et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003, 423:550-555.
85. Baranowski M. Biological role of liver X receptors. J. Physiol. Pharmacol. 2008, 59(Suppl. 7):31-55.
86. Oh J., et al. Deletion of macrophage Vitamin D receptor promotes insulin resistance and monocyte cholesterol transport to accelerate atherosclerosis in mice. Cell Rep. 2015, 10:1872-1886.
87. Herman M.A., et al. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 2012, 484:333-338.
88. Iizuka K., et al. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:7281-7286.
89. Oosterveer M.H., et al. LRH-1-dependent glucose sensing determines intermediary metabolism in liver. J. Clin. Invest. 2012, 122:2817-2826.
90. Wang Z., et al. The transcriptional coactivators p/CIP and SRC-1 control insulin resistance through IRS1 in obesity models. PLoS ONE 2012, 7:e36961.
91. Li P., et al. Adipocyte NCoR knockout decreases PPARgamma phosphorylation and enhances PPARgamma activity and insulin sensitivity. Cell 2011, 147:815-826.
92. Hogan M.F., et al. Hepatic insulin resistance following chronic activation of the CREB coactivator CRTC2. J. Biol. Chem. 2015, 290:25997-26006.
93. Puigserver P. Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha. Int. J. Obes. (Lond.) 2005, 29(Suppl. 1):S5-S9.
94. Michael L.F., et al. Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:3820-3825.
95. Puigserver P., Spiegelman B.M. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr. Rev. 2003, 24:78-90.
96. Yoshizaki T., et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol. Cell. Biol. 2009, 29:1363-1374.
97. Schenk S., et al. Sirt1 enhances skeletal muscle insulin sensitivity in mice during caloric restriction. J. Clin. Invest. 2011, 121:4281-4288.
98. Li Y., et al. Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver. FASEB J. 2011, 25:1664-1679.
99. Yoshizaki T., et al. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am. J. Physiol. Endocrinol. Metab. 2010, 298:E419-E428.